Cargando…
Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score
OBJECTIVE: To analyze the effectiveness of combining immune checkpoint inhibitors (ICIs) with first-line therapy in patients with advanced biliary tract cancer (BTC) and explore the biomarkers affecting the prognosis of immunotherapy, to construct a nomogram for the prediction of survival. METHODS:...
Autores principales: | Zhang, Zhengfeng, Wang, Dazhen, Zhang, Jianji, Ruan, Yuli, Zhao, Lu, Yang, Liu, Liu, Ze, Yang, Lei, Lou, Changjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576733/ https://www.ncbi.nlm.nih.gov/pubmed/37668711 http://dx.doi.org/10.1007/s00262-023-03513-4 |
Ejemplares similares
-
Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors
por: Zhang, Zhengfeng, et al.
Publicado: (2023) -
Retrospective study of the combination of TP and PF regimens with or
without immune checkpoint inhibitors for the first-line treatment of locally
advanced or advanced esophageal squamous cell carcinoma
por: Zhang, Zhengfeng, et al.
Publicado: (2023) -
Case Report: A case of advanced duodenal adenocarcinoma in complete remission after chemotherapy combined with targeted therapy and radiotherapy
por: Zhang, Zhengfeng, et al.
Publicado: (2022) -
A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma
por: Zeng, Jie, et al.
Publicado: (2023) -
Chemotherapy for Biliary Tract Cancer in 2021
por: Sasaki, Takashi, et al.
Publicado: (2021)